Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Salivary carcinosarcoma: insight into multistep pathogenesis indicates uniform origin as sarcomatoid variant of carcinoma ex pleomorphic adenoma with frequent heterologous elements

S. Ihrler, D. Stiefel, P. Jurmeister, A. Sandison, N. Chaston, J. Laco, N. Zidar, L. Brcic, R. Stoehr, A. Agaimy

. 2023 ; 82 (4) : 576-586. [pub] 20221207

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004042

AIMS: The formal pathogenesis of salivary carcinosarcoma (SCS) remained unclear, both with respect to the hypothetical development from either preexisting pleomorphic adenoma (PA) or de novo and the clonal relationship between highly heterogeneous carcinomatous and sarcomatous components. METHODS AND RESULTS: We performed clinicopathological and molecular (targeted RNA sequencing) analyses on a large series of 16 cases and combined this with a comprehensive literature search (111 cases). Extensive sampling (average 11.6 blocks), combined with immunohistochemistry and molecular studies (PA-specific translocations including PLAG1 or HMGA2 proven in 6/16 cases), enabled the morphogenetic identification of PA in 15/16 cases (93.8%), by far surpassing a reported rate of 49.6%. Furthermore, we demonstrated a multistep (intraductal/intracapsular/extracapsular) adenoma-carcinoma-sarcoma-progression, based on two alternative histogenetic pathways (intraductal, 56.3%, versus myoepithelial pathway, 37.5%). Thereby, early intracapsular stages are identical to conventional carcinoma ex PA, while later extracapsular stages are dominated by secondary, frequently heterologous sarcomatous transformation with often large tumour size (>60 mm). CONCLUSION: Our findings strongly indicate that SCS (almost) always develops from PA, with a complex multistep adenoma-carcinoma-sarcoma-sequence, based on two alternative histogenetic pathways. The findings from this novel approach strongly suggest that SCS pathogenetically is a rare (3-6%), unique, and aggressive variant of carcinoma ex PA with secondary sarcomatous overgrowth. In analogy to changes of terminology in other organs, the term "sarcomatoid carcinoma ex PA with/without heterologous elements" might be more appropriate.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004042
003      
CZ-PrNML
005      
20230425141044.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/his.14840 $2 doi
035    __
$a (PubMed)36376255
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ihrler, Stephan $u DERMPATH Muenchen, Munich, Germany $u Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany $1 https://orcid.org/0000000261830249
245    10
$a Salivary carcinosarcoma: insight into multistep pathogenesis indicates uniform origin as sarcomatoid variant of carcinoma ex pleomorphic adenoma with frequent heterologous elements / $c S. Ihrler, D. Stiefel, P. Jurmeister, A. Sandison, N. Chaston, J. Laco, N. Zidar, L. Brcic, R. Stoehr, A. Agaimy
520    9_
$a AIMS: The formal pathogenesis of salivary carcinosarcoma (SCS) remained unclear, both with respect to the hypothetical development from either preexisting pleomorphic adenoma (PA) or de novo and the clonal relationship between highly heterogeneous carcinomatous and sarcomatous components. METHODS AND RESULTS: We performed clinicopathological and molecular (targeted RNA sequencing) analyses on a large series of 16 cases and combined this with a comprehensive literature search (111 cases). Extensive sampling (average 11.6 blocks), combined with immunohistochemistry and molecular studies (PA-specific translocations including PLAG1 or HMGA2 proven in 6/16 cases), enabled the morphogenetic identification of PA in 15/16 cases (93.8%), by far surpassing a reported rate of 49.6%. Furthermore, we demonstrated a multistep (intraductal/intracapsular/extracapsular) adenoma-carcinoma-sarcoma-progression, based on two alternative histogenetic pathways (intraductal, 56.3%, versus myoepithelial pathway, 37.5%). Thereby, early intracapsular stages are identical to conventional carcinoma ex PA, while later extracapsular stages are dominated by secondary, frequently heterologous sarcomatous transformation with often large tumour size (>60 mm). CONCLUSION: Our findings strongly indicate that SCS (almost) always develops from PA, with a complex multistep adenoma-carcinoma-sarcoma-sequence, based on two alternative histogenetic pathways. The findings from this novel approach strongly suggest that SCS pathogenetically is a rare (3-6%), unique, and aggressive variant of carcinoma ex PA with secondary sarcomatous overgrowth. In analogy to changes of terminology in other organs, the term "sarcomatoid carcinoma ex PA with/without heterologous elements" might be more appropriate.
650    _2
$a lidé $7 D006801
650    12
$a pleomorfní adenom $x patologie $7 D008949
650    12
$a nádory slinných žláz $x patologie $7 D012468
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    12
$a adenokarcinom $7 D000230
650    12
$a karcinosarkom $7 D002296
650    12
$a nádory měkkých tkání $7 D012983
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stiefel, David $u Dental School, Ludwig-Maximilians-University, Munich, Germany
700    1_
$a Jurmeister, Philipp $u Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany
700    1_
$a Sandison, Ann $u Department of Head Neck Oral Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK
700    1_
$a Chaston, Nicola $u Department of Pathology, East Kent Hospitals University NHS Foundation Trust, Ashford, UK
700    1_
$a Laco, Jan $u Fingerland Department of Pathology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Králové, Czech Republic
700    1_
$a Zidar, Nina $u Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/0000000168663220
700    1_
$a Brcic, Luka $u D&R Institute of Pathology, Medical University of Graz, Graz, Austria $1 https://orcid.org/0000000290988416
700    1_
$a Stoehr, Robert $u Institute of Pathology, Friedrich-Alexander University, Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany
700    1_
$a Agaimy, Abbas $u Institute of Pathology, Friedrich-Alexander University, Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany $1 https://orcid.org/0000000204458161
773    0_
$w MED00002043 $t Histopathology $x 1365-2559 $g Roč. 82, č. 4 (2023), s. 576-586
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36376255 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141041 $b ABA008
999    __
$a ok $b bmc $g 1924604 $s 1190251
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 82 $c 4 $d 576-586 $e 20221207 $i 1365-2559 $m Histopathology $n Histopathology $x MED00002043
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace